Veerhealth Care Limited has submitted newspaper publication documents to BSE Limited regarding the postal ballot notice for preferential warrant issuance, following the board approval granted on March 28, 2026. The company filed the regulatory compliance documentation under Regulation 47 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

BSE Submission and Regulatory Compliance

The company submitted official documentation to BSE on April 01, 2026, confirming newspaper publication of the postal ballot notice extract. Managing Director Bhavin S. Shah (DIN: 03129574) signed the submission letter, ensuring compliance with mandatory disclosure requirements.

E-Voting Schedule and Process

The postal ballot notice establishes a comprehensive e-voting framework for shareholder approval of the preferential warrant allotment. The cut-off date for determining eligible shareholders has been set as March 27, 2026, with voting rights proportional to shareholding as of this date.

Warrant Issue Structure and Allocation

The preferential issue comprises up to 1,00,00,000 fully convertible warrants at Rs 20.25 per warrant, totaling Rs 20.25 crores. The warrants provide rights to subscribe to equivalent equity shares of face value Rs 10 each within 18 months from allotment.

Fund Utilization and Corporate Objectives

The company has outlined specific deployment strategies for the Rs 20.25 crores proceeds, focusing on manufacturing capacity expansion and operational enhancement. The funds will support plant and machinery acquisition, electrical and electronics installation, furniture and fixtures, office equipment including computers and software, and general corporate purposes.

Regulatory Compliance and Pricing Framework

The warrant issue price of Rs 20.25 per warrant has been determined in accordance with Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The relevant date for minimum price computation is March 31, 2026, with the issue price exceeding both the market-based minimum of Rs 20.10 and the independent valuation report threshold.

Proposed allottees must pay at least 25% of the warrant issue price before allotment, with the remaining 75% payable upon exercising conversion rights. The warrants and resulting equity shares will be subject to lock-in provisions as per SEBI ICDR Regulations, with allotment to be completed within 15 days of shareholder approval.

Veerhealth Care Limited has announced a board meeting to deliberate on fund raising proposals, marking a significant corporate development for the Mumbai-based company. The announcement was made through an official regulatory filing under Regulation 29(1)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's commitment to regulatory compliance and transparent stakeholder communication.

Board Meeting Details

The board meeting has been scheduled with specific parameters as outlined in the company's regulatory filing dated March 20, 2026:

Fund Raising Proposal Overview

The board will consider and approve proposals for raising funds through multiple financial instruments. The company has outlined several potential funding mechanisms to provide flexibility in its capital raising strategy:

• Equity shares issuance
• Convertible securities
• Preferential Issue
• Rights Issue
• Qualified Institutional Placement (QIP)
• Other modes as deemed appropriate

All proposed funding methods will be subject to necessary regulatory approvals and compliance requirements as mandated under applicable securities regulations.

Trading Window Closure

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's Code of Conduct for Prevention of Insider Trading, Veerhealth Care Limited has implemented a trading window closure. The restriction affects designated persons and their relatives, preventing them from dealing in the company's securities from the date of intimation until 48 hours after the board meeting concludes.

Shareholder Approval Process

The board will also deliberate on convening an Extraordinary General Meeting or initiating a Postal Ballot process to obtain shareholder approval for the proposed fund raising initiative. This step ensures compliance with regulatory requirements and maintains transparency in corporate governance practices.

Company Information

Veerhealth Care Limited operates under CIN L65910MH1992PLC067632 and trades on BSE under the code 511523. The regulatory filing was signed by Managing Director Bhavin S. Shah (DIN: 03129574), reflecting the company's adherence to proper corporate governance and regulatory disclosure norms.